To include your compound in the COVID-19 Resource Center, submit it here.

Met-ing the neighbors

AstraZeneca cancer deal validates Hutchison's in-house discovery in China

AstraZeneca plc's grassroots approach to business development in Asia has allowed it to bring in a program from Hutchison MediPharma Ltd. that was under the radar of analysts covering the Chinese company. The deal to develop an inhibitor of c-Met receptor tyrosine kinase also provides the first validation of the 10 years and almost $100 million the Chinese biotech has spent building its in-house discovery operations.

Hutchison MediPharma was established in 2002 to screen Chinese traditional medicines in search of pharmaceuticals. The company is a subsidiary of U.K.-listed Hutchison China MediTech Ltd. (Chi-Med), which itself is a unit of Hong Kong-listed multinational conglomerate Hutchison Whampoa Ltd.

"People probably don't realize that Hutchison MediPharma has been in place in Shanghai now for 10

Read the full 1207 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers